rNAPc2 - Anticoagulant - TF-FVIIa complex inhibitor

Nematode anticoagulant protein c2 (rNAPc2) is a recombinant version of a naturally occurring protein that blocks the coagulation cascade by inhibiting the TF-FVIIa complex. Results from phase I clinical trials indicate that rNAPc2 is well tolerated following single and repeated s.c. and i.v. administration in healthy volunteers. No adverse events and no substantial bleeding episodes were observed. Clinical studies in patients showed that rNAPc2 is a safe and effective strategy for the prevention of thrombotic events after total knee replacement and elective coronary angioplasty. rNAPc2 is currently undergoing phase II investigation for the treatment of acute coronary syndrome. Moreover, the efficacy of rNAPc2 as a promising therapeutic option to inhibit coagulation activation in sepsis has been demonstrated in both animal models and patients. rNAPc2 has been also shown to protect against Ebola virus infection in primates, as well as to possess potential as an inhibitor of tumor growth in vivo.